Saçıntı Koray Görkem, Şükür Yavuz Emre, Sönmezer Murat, Somer Atabekoğlu Cem
Ankara University School of Medicine, Department of Obstetrics and Gynaecology, Ankara, Turkey. Email:
Ankara University School of Medicine, Department of Obstetrics and Gynaecology, Ankara, Turkey.
Int J Fertil Steril. 2021 Oct;15(4):303-304. doi: 10.22074/IJFS.2021.523540.1081. Epub 2021 Oct 16.
Although ovarian tissue cryopreservation is still considered as an experimental technique, several authors from around the world have reported successful and promising results. Currently, oocyte cryopreservation seems to be the most feasible technique for fertility preservation when there's some kind of a time constraint in adolescents and adults. However, it has been estimated that a young woman would be expected to have a 94% likelihood of having a live birth with 20 mature frozen oocytes (1). At age 34 years, however, this expectation is decreased to 90% with 20 mature frozen oocytes. In addition to age-related limitations, an immediate obstacle for obtaining oocytes in cancer patients is the fact that only one controlled ovarian hyperstimulation (COH) cycle can usually be performed in these women because of time constraints, yielding a relatively low number of oocytes and/or embryos. For this reason, results from egg donation programs cannot be extrapolated to cancer patients, nor can the quality of oocytes be guaranteed. Hence, a combined fertility preservation technique can be of valuable in increasing the chances of successful future pregnancies following gonadotoxic cancer therapies. Previously, Dolmans et al. (2) suggested that cryopreservation of bilateral ovarian cortex followed by COH is a feasible and safe approach to preserve fertility before gonadotoxic treatment, and that the number of cryopreserved embryos was similar to the controls. We have been offering the option of the combined technique to fertility preservation patients for a couple of years and have performed it in a series of eight candidate patients. All patients had enough time for COH before oncology treatments. We first performed laparoscopic ovarian resection for ovarian tissue cryopreservation and then started COH on postoperative day 0 or 1 in each patient (Table 1). The main point in our findings is that ovarian resection is performed from the side with less antral follicle count of the patients. We suggest that this approach can increase the oocyte yield in a single available COH cycle. The data is limited on the effectiveness of combined technique and more long-term follow-up studies are needed in larger groups with appropriate controls. According to our clinical experience, we believe that combined technique is a valid approach, which is expanding beyond the experimental stage and has become a clinical technique for fertility preservation. We particularly suggest selecting the ovary with a low antral follicle count for wedge resection to increase oocyte yield. The information gathered from large international multicenter reports would encourage physicians to agree that the method should complete the experimental phase and be ready for wider clinical use in female fertility preservation.
尽管卵巢组织冷冻保存仍被视为一种实验性技术,但来自世界各地的多位作者已报道了成功且有前景的结果。目前,当青少年和成年人存在某种时间限制时,卵母细胞冷冻保存似乎是生育力保存最可行的技术。然而,据估计,年轻女性若有20枚成熟冷冻卵母细胞,其活产概率为94%(1)。然而,在34岁时,有20枚成熟冷冻卵母细胞的情况下,这一预期降至90%。除了与年龄相关的限制外,癌症患者获取卵母细胞的一个直接障碍是,由于时间限制,这些女性通常只能进行一个控制性卵巢刺激(COH)周期,从而产生相对较少数量的卵母细胞和/或胚胎。因此,卵子捐赠项目的结果不能外推至癌症患者,卵母细胞的质量也无法得到保证。因此,联合生育力保存技术对于增加性腺毒性癌症治疗后未来成功怀孕的几率可能具有重要价值。此前,多尔曼斯等人(2)提出,在性腺毒性治疗前,双侧卵巢皮质冷冻保存后进行COH是一种可行且安全的生育力保存方法,冷冻保存的胚胎数量与对照组相似。几年来,我们一直为有生育力保存需求的患者提供联合技术选择,并已在一系列8例候选患者中实施。所有患者在接受肿瘤治疗前都有足够的时间进行COH。我们首先进行腹腔镜卵巢切除术以冷冻保存卵巢组织,然后在术后第0天或第1天开始对每位患者进行COH(表1)。我们研究结果的重点是,卵巢切除术是在患者窦卵泡计数较少的一侧进行的。我们认为这种方法可以在单个可用的COH周期中提高卵母细胞产量。关于联合技术有效性的数据有限,需要在有适当对照的更大群体中进行更多长期随访研究。根据我们的临床经验,我们认为联合技术是一种有效的方法,它已超越实验阶段,成为一种用于生育力保存的临床技术。我们特别建议选择窦卵泡计数低的卵巢进行楔形切除以提高卵母细胞产量。从大型国际多中心报告中收集的信息将促使医生们一致认为该方法应完成实验阶段,并准备好在女性生育力保存中更广泛地临床应用。